Daniel Meron

Partner
Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
Profile Experience

Daniel Meron is Co-Chair of the firm’s Healthcare Services & Providers Industry Group. He served previously as Global Co-Chair of the firm’s Healthcare & Life Sciences Practice Group. Mr. Meron brings to his practice his unique experience as a high-level official at both the Department of Justice and the Department of Health and Human Services.

Mr. Meron’s practice focuses on representing members of the healthcare industry in complex and high stakes disputes with the government. He has particular expertise in False Claims Act and related civil investigations, legal challenges to the validity of agency regulations and policies, and providing sophisticated compliance counseling. His clients include plans, providers, PBMs, specialty pharmacies and pharmaceutical, biotech, and medical device manufacturers.

Mr. Meron is consistently recognized as one of the leading healthcare lawyers in the country. His prominent litigation successes earned him the National Law Journal’s accolade of Healthcare Law Trailblazer (2019) and, among numerous other recognitions, he has twice been named by Law360 a Healthcare MVP (2016, 2019) and recommended in Who's Who Legal: Healthcare 2020. He has been repeatedly named a leading lawyer by The Legal 500 US and Chambers USA, in which sources applaud him for his “quality, reliable advice in time-sensitive situations.” In addition, Legal Media Group — a part of Euromoney Institutional Investor PLC — has identified Mr. Meron as one of the “stars” in the area of government investigations and fraud & abuse (2013-2016) and Nightingale’s Healthcare News named him one of the top 10 outstanding healthcare fraud and compliance lawyers.

Mr. Meron joined Latham from the United States Department of Health and Human Services (HHS), where he served as General Counsel from 2006 to 2007. At HHS, he advised the Department’s leadership on sensitive and high-priority matters involving all of the key statutes and regulations that HHS enforces, including the Food, Drug and Cosmetic Act and the Medicare and Medicaid statutes, as well as the federal Anti-Kickback Statute.

As general counsel, Mr. Meron also worked closely with the Office of Inspector General in coordinating positions on enforcement matters relating to FDA and CMS statutes and regulations.

From 2003 to 2006, Mr. Meron was the Principal Deputy Assistant Attorney General for the Civil Division of the US Department of Justice. His duties as Principal Deputy included oversight of the Division’s healthcare civil fraud (False Claims Act) and off-label promotion prosecutions, as well as defense of FDA and CMS regulations, policies and reimbursement decisions.

Mr. Meron served as a law clerk to Justice Anthony M. Kennedy of the US Supreme Court and to Judge Laurence H. Silberman of the US Court of Appeals for the DC Circuit.

Mr. Meron has argued over 25 cases in the US federal courts of appeals, including two appeals “en banc,” as well as numerous dispositive motions in the federal district courts.

Mr. Meron’s recent experience includes:

  • Successfully defended UnitedHealth in a high profile False Claims Act suit brought by the Department of Justice, obtaining dismissal of DOJ’s entire complaint
  • Represented three large drug manufacturers in successful challenge to CMS’s DTC List Price Disclosure Rule
  • Represented West Coast medical device manufacturer in off label and reimbursement investigation
  • Obtained outright dismissal, and affirmance on appeal, of first post-amendment FCA suit based on alleged inflated AWP reporting
  • On behalf of a healthcare company, brought successful APA challenge to CMS’s Part C Overpayment Regulation
  • Represented large specialty pharmacy in successful resolution of first DOJ false claims act suit based on drug adherence program
  • Obtained dismissal of FCA suit challenging health plan’s gift card health reward program as an alleged kickback
  • Represented hospital in a national DOJ investigation into billing for cardiac devices; matter closed with no payment
  • Successfully argued before the district court and the First Circuit that the University of Massachusetts Medical School should enjoy 11th Amendment Immunity from FCA suit
  • Successfully defended senior executives of a large nursing home chain in HHS OIG exclusion proceeding; matter closed with no action
Publication
  • Medicare & Medicaid Reimbursement for Off-Label Uses of Pharmaceuticals and Medical Devices, in OFF-LABEL COMMUNICATIONS: A GUIDE TO SALES & MARKETING COMPLIANCE (Mark Levy ed., Food and Drug Law Inst. 3d ed. 2012)
Selected Speaking Engagements
  • “The Time is Still Now: Medicare Advantage/Medicaid Managed Care At the Forefront of Enforcement,” American Health Lawyers Association Fraud and Compliance Forum (2019)
  • Webex, “Under the Microscope: Making Sense of Today’s Health Care Enforcement Landscape” (2018)
  • “Managed Care: Fraud and Compliance”, Health Care Compliance Association’s 22nd Annual Compliance Institute (2018)
  • “Fraud and Compliance Issues for Commercial, Medicare and Medicaid Managed Care Organizations,” ABA National Institute on Health Care Fraud (2018)
  • “Statistical Sampling and False Claims Act Liability: Aseracare,” State Bar of Georgia Healthcare Fraud Institute (2017)
  • “Medicare Part C Fraud,” 3rd Annual Conference, Qui Tam – False Claims Act Litigation (2016)
  • “Introduction to Fraud and Compliance for Commercial Payors and Managed Care Organizations,” ABA National Institute on Healthcare Fraud (2015)
  • Guest Lecturer, Cornell Law School, “Materiality under the False Claims Act (Spring 2013)
  • “Recent Developments in FCA Liability,” ABA National Institute on Civil FCA and Qui Tam Enforcement (2012)
  • “Trends in Enforcement of Off-Label Promotion and Anti-Kickback Prohibitions as Bases for False Claims Act Prosecutions,” AdvaMed MedTech Conference (September 21, 2008)
  • “New Trends in Medical Device Fraud and Abuse/Off-Label Promotion Enforcement,” MDMA Medical Technology Executive Forum (October 15, 2008)
  • “How Important Is an Indication? Off Label Promotion and Compendia: The Interplay between Compendia Listings of Unapproved Indications and False Claims Act Liability,” FDLI Conference on Better Understanding CMS and its Relationship to FDA, (November 19, 2008)
  • “Commercial Speech: What Can The Constitution Protect? A Moot Appellate Court, Analysis of Off-Label Promotion of Medical Devices and the Constitution,” FDLI/FDA 51st Annual Conference, Washington, D.C. (March 27, 2008)
  • “Major Legal Developments Affecting the Pharmaceutical and Biotechnology Industries: From the Food and Drug Administration Amendments Act of 2007 to the Supreme Court’ Preemption Docket and Beyond,” Luncheon Address at the FDLI Board of Directors Annual Meeting (October 2007)
  • “The Increasing Interplay of ‘Life Sciences’ and ‘Healthcare’ Law,” Keynote Address, American Health Lawyers Association Life Sciences Institute, San Francisco, CA (April 26, 2007)
  • “Legal Developments Relevant to the FDA’s Authority,” Address to the 50th Annual FDLI/FDA Annual Conference, Bethesda, MD (April 12, 2007)
Thought Leadership
  • “11th Circuit: Difference in Opinion Not Enough for FCA Liability” – Latham & Watkins Client Alert, September 13, 2019
  • “Drug Pricing and Payment Policy: Sweeping HHS Rebate Reform Proposal and First 2019 Congressional Hearings” – Latham & Watkins Client Alert, February 5, 2019
  • “Drug Pricing and Payment Policy: Key 2018 Developments and Potential 2019 Changes and Challenges” – Latham & Watkins Client Alert, January 7, 2019
  • “ACA “Repeal and Replace” Bill Merits Attention from Industry Stakeholders,” Latham & Watkins Client Alert (May 2017)
  • “Fourth Circuit Declines to Address Use of Statistical Sampling in False Claims Act Cases,” Latham & Watkins Client Alert (February 2017)
  • “President Obama Signs the 21st Century Cures Act Into Law,” Latham & Watkins Client Alert (December 2016)
  • “SCOTUS Upholds Implied Certification for Some Cases But Imposes “Rigorous Materiality Requirement” for FCA Liability,” Latham & Watkins Client Alert (June 2016)
  • “Amarin Settles Off-Label Promotion Case Against the FDA,” Latham & Watkins Client Alert (March 2016)
  • “Fourth Circuit May Address Use of Statistical Sampling in False Claims Act Actions,” Latham & Watkins Client Alert (July 2015)
  • “We’ve Got Washington Covered - Agency Insight Series,” Latham & Watkins Newsletter (March 2014)
  • “CMS Proposes Major Changes to Overpayment Reporting Requirements, Extending Liability to Ten Years,” Latham & Watkins Client Alert (March 2012)
  • “Recently Announced Interagency Medicare Fraud Initiative Expands Ongoing Enforcement Activity,” Latham & Watkins Client Alert (June 2009)
  • “FDA Issues a Final Guidance on ‘Good Reprint Practices,’” Latham & Watkins Client Alert (January 2009)
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.